Considering the need to shorten lenght of stays, Rivaroxaban, indeed will likely be embraced immediately as soon as it becomes available.
RECORD4: More impressive data on rivaroxaban in VTE prevention
Nice, France- The new oral anticoagulant rivaroxaban (Johnson & Johnson/Bayer) showed superior efficacy compared with the US-approved dosing regimen of enoxaparin in preventing venous thromboembolism (VTE) in patients who had undergone total-knee-replacement surgery in the RECORD4 trial [1].
Rivaroxaban is one of several potential new oral anticoagulants in development. First indications will be in preventing VTE after surgery, but these agents are also being developed as replacements for warfarin for the prevention of stroke in atrial-fibrillation patients and for the treatment of acute coronary syndromes.
http://www.theheart.org/article/872775.do
Rivaroxaban reminds me of Exenta, the AstraZenica anticoagulant that the FDA nixed at the last moment due to findings of hepatic inflamation. It seemed that the drug was a shoe-in, but on 11/2006 it was suddenly denied approval.
So far it looks like rivaroxaban's liver toxicity is very infrequent. I hope that it gets approved...
Al Borges, M.D.
● Oncologist in a Small Group Practice in Virginia
● My website URL: http://msofficeemrproject.com/
July 1, 2008 | Sue Hughes
Hamilton, ON - Three trials of the new oral anticoagulant rivaroxaban, showing impressive results in the prevention of venous thromboembolism (VTE) in patients undergoing orthopedic surgery, were published last week. A pooled analysis from RECORD1, 2, and 3 has also shown superiority of rivaroxaban over enoxaparin in preventing VTE without increasing bleeding.
The RECORD1 and 3 trials are published in the June 26, 2008, issue of the New England Journal of Medicine [1,2], while the RECORD2 trial is published online in the Lancet on June 25, 2008 [3]. All three trials have been presented previously (and reported by heartwire) at various medical meetings. A fourth similar trial (RECORD4) was presented earlier this month at the 2008 Congress of the European Federation of National Associations of Orthopaedics and Traumatology.
http://www.theheart.org/viewArticle.do?primaryKey=878097&nl_id=tho08jul08